MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma
Andrea Lampis(Institute of Cancer Research), Chiara Braconi(Beatson West of Scotland Cancer Centre), Michele Simbolo(University of Verona), Nicos Fotiadis(Royal Marsden NHS Foundation Trust), Chirag Nepal(University of Copenhagen), Luciano Cascione(Institute of Oncology Research), Sijia Yu(Shenyang Pharmaceutical University), Jesper B. Andersen(University of Copenhagen), Jens C. Hahne(Institute of Cancer Research), Blanka Hezelova(Royal Marsden NHS Foundation Trust), Paul A. Clarke(Institute of Cancer Research), Matteo Fassan(University of Padua), Georgios Vlachogiannis(Institute of Cancer Research), David Cunningham(Royal Marsden NHS Foundation Trust), Else Bosma(Institute of Cancer Research), Pierluigi Gasparini(The Ohio State University), Maria Antonietta Bali(Royal Marsden NHS Foundation Trust), Khurum Khan(Institute of Cancer Research), Somaieh Hedayat(Institute of Cancer Research), Rosemary Burke(Institute of Cancer Research), Carlo M. Croce(The Ohio State University), Elizabeth Smyth(National Health Service), Pietro Carotenuto(Telethon Institute Of Genetics And Medicine), Nicola Valeri(Royal Marsden NHS Foundation Trust), Mark Stubbs(Institute of Cancer Research), Rebecca Cole(Institute of Cancer Research), Zakaria Eltahir(Royal Marsden NHS Foundation Trust), Ruwaida Begum, Javier Fernández-Mateos(Universidad de Oviedo), Vincenza Guzzardo(University of Padua), Andrew Wotherspoon(Université Libre de Bruxelles), Aldo Scarpa(University of Verona), Suzanne A. Eccles(Discovery Centre), Paul Workman(Institute of Cancer Research)
Cited by 115
Related Papers
Gastric cancer
|The Lancet|2020|4.8k
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
The role of MicroRNAs in human cancer
|Signal Transduction and Targeted Therapy|2016|2.5k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k